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Abstract Despite all major breakthroughs in recent years of research, we are still unsuccessful to 15 
effectively diagnose and treat cancer that has express and metastasizes. Thus, the development of a novel 16 
approach for cancer detection and treatment is crucial. Recent progress in Glyconanotechnology has 17 
allowed the use of glycans and lectins as bio-functional molecules for many biological and biomedical 18 
applications. With the known advantages of Quantum Dots (QDs) and versatility of carbohydrates and 19 
lectins, Glyco-functionalised QD is a new prospect in constructing biomedical imaging platform for cancer 20 
behaviour study as well as treatment. In this review, we aim to describe the current utilisation of Glyco-21 
functionalised QDs as well as their future prospective to interpret and confront cancer. 22 
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1 Introduction 24 
Cancer is one of the leading causes of death and a major threat to public health in the 21st century. Cancer 25 
is a complex type of disease affecting a verity of tissues. It is mainly characterised by uncontrolled growth 26 
of abnormal cells, with the ability to attack surrounding tissues and possibly metastasize. Despite of early 27 
stage diagnosis and therapeutics help to manage the disease, it remains to be never ending battle to prevent 28 
and treat cancer. Nanotechnology is a promising approach in diagnosis and treatment of cancer through 29 
the development of novel diagnostic imaging methods and targeted therapies. Quantum Dots (QDs) are 30 
being intensively studied as a novel probe for Biomedical imaging both in vitro and in vivo due to their 31 
unique optical and electronic properties. Extensive researches on the physicochemical properties of QDs, 32 
such as size, morphology, composition, and surface features suggest that QDs have great potential in 33 
cancer detection and treatment[1-6]. When conjugated with antibodies, peptides or other small biological 34 
molecules, QD-based probes can be used to target cancer cells with high specificity and sensitivity. 35 
During the last decade, there has been a great deal of interest in the incorporation of nanotechnology 36 
with carbohydrates. Carbohydrates are prominently exposed on the surface of living cells and are critically 37 
involved in cell−cell interactions and regulate important biological functions such as cell growth and cell 38 
differentiation[7]. Cancer cells differ from normal cells in many aspects, which are often exploited as a 39 
strategy in cancer chemotherapy. Cancer cell undergoes a high rate of glycolysis to adapt the low oxygen 40 
environment, leading to increased glucose demand called Warburg effect. High glucose demand leads to 41 
overexpression of insulin independent glucose transporter GLUT-1. Overexpressed GLUT-1 can be a 42 
potential target for chemotherapy. Glycoconjugates and carbohydrate derivatives can be effectively used 43 
for chemotherapy and also, conjugation of sugars to a known anti-cancer agent can increase the selectivity 44 
and hence reduce the toxicity[8]. The advances in nanotechnology have allowed the creation of different 45 
bioactive Glyco-functionalised nanostructures for various biomedical applications such as drug delivery, 46 
gene therapy, pathogen detection and lectin-based biosensors [9-15].  47 
Lectins were first introduced at the end of 19 century and are described as carbohydrate-binding 48 
proteins[16]. Lectins play important role in many biological process and living organism[17,18]. They are 49 
universally spread in nature and are also major component of the outer surface of mammalian cells. They 50 
have been widely used in researches involving carbohydrates recognition and detection on cell 51 
surfaces[19,20]. Several studies have conjugated carbohydrates and lectins to different nanostructures, 52 
such as polymers, liposomes, dendrimers, carbon nanotubes, metal nanoparticles and quantum dots[9,14]. 53 
The resulting Glyco-functionalised nanoparticles have been used for cell imaging, cell separation, protein 54 
detection and enzyme immobilization[15]. Glyconanoparticles presented a highly multivalent method of 55 
interaction with cell surface structure like glycoprotein and glycolipid (Error! Reference source not 56 
found.). The major function of Glyconanoparticles is to serve as recognition markers[21]. In particular, 57 
carbohydrate-protein interactions on normal cells and their malignant counterparts show significant 58 
differences[22], which is important strategy in cancer chemotherapy. Although Carbohydrate−protein 59 
interactions are typically very weak but possess key role to biological processes that require temporary 60 
adhesion during cell adhesion, cancer metastasis, immune response and intracellular trafficking[15]. 61 
Moreover carbohydrate perform as essential intermediate in endocytosis processes, intercellular 62 
interaction and extracellular matrix, adhesion and cell growth[23,24], fertilisation[25], and also interactions 63 
between pathogen and host[26]. The unique functionalities of carbohydrates forming densely packed 64 
cluster on the surface of nanoparticles (NPs) is known as the “glycocluster effect”[27,28]. These 65 
glyconanoparticles behaves in a similar manner to mimic the naturally occurring glycocalyx. Therefore, 66 
the functionalisation and engineering of these Glyconanoaprticles helps to further enhance their specific 67 
reorganisation properties on multivalent scaffolds in glycoscience.  68 
 69 
Fig. 1 Scheme of the cell membrane carbohydrate residues labelling with lectin-QDs. 70 
2 Characteristic of Quantum Dots for Biomedical Application 71 
Quantum dots are semiconductors nanocrystals, are one of the first nanotechnologies to be integrated with 72 
the biological sciences. Quantum dots are proven to be powerful probes for fluorescence imaging and are 73 
being developed for a range of additional applications including the detection of cancer, fluorescent assays 74 
for drug discovery, single protein tracking, and intracellular reporting. Quantum dots have distinct 75 
properties that give them their unique capabilities.  76 
QDs were first fabricated in the 80’s by Louis E. Brus[29] and the unique properties of these special 77 
nano-structures attracted interest from many fields. QDs are semiconductor nano-crystals in which 78 
excitons are confined in all three spatial dimensions. The confinement can be realised by fabricating the 79 
semiconductor in very small size, typically several hundred to thousands of atoms per particle. Due to 80 
quantum confinement effects, QDs act like artificial atoms, showing controllable discrete energy levels. 81 
QDs range from 2 nm to 10 nm in diameter and shows unique optical, physical and chemical properties. 82 
They offer great advantages over traditional organic fluorescent dyes. They present several beneficial 83 
characteristics for spectroscopy and microscopy, such as high fluorescence intensity, long lifetime, and 84 
good resistance to photobleaching. The brightness of QD based multifunctional probes affords high 85 
sensitivity for simultaneous cancer molecular imaging and targeted therapy. For spectrum application, the 86 
sensitivity of QD-based molecular imaging can be two to three orders larger than that of routine fluorescent 87 
dyes[30]. Furthermore, the fluorescence near-infrared (NIR) of NIR-QDs can be detected in deep tissues, 88 
making them suitable for in vivo imaging with high signal to background ratio. These properties are 89 
enabling a new generation of fluorescence imaging experiments in cancer research allowing investigators 90 
to unravel biological function at the molecular level. When functionalized with diagnostic and therapeutic 91 
agents, QDs can be used for cancer diagnosis, photodynamic therapy, cell labelling and biosensors. 92 
Biocompatibility and biological targeting of QDs are achieved through surface modification and 93 
conjugation with antibodies, peptides, or small molecules. The glyconanoparticles shows promising results 94 
in fluorescence-based techniques for biological studies when associated with QDs to lectins or 95 
carbohydrate.   96 
2.1 Lectin-functionalised QDs in Cancer Diagnosis and Theranostics 97 
In 1998, first biocompatible QDs were announced for cancer imaging in in vitro. Despite of immeasurable 98 
technological advances thereafter in cancer diagnosis, the conventional medical imaging techniques in 99 
most of cases fail to offer sensitivity and resolution altogether for early stage diagnosis, as well as 100 
providing specific disease molecular information. Signal-to-background ratio is important and needs lot 101 
of improvement in order to effectively screening, staging and treatment of cancer. To achieve that 102 
proportional improvements in sensitivity and contrast targeting agent are required. The objective of cancer 103 
imaging is to detect and image the smallest number of tumour cells, ideally before the angiogenesis[31,32]. 104 
Current detection for solid tumours has a threshold of 109 cells[31,33]. When assisted by the 105 
administration of specific exogenous contrast agents[34-37], current imaging modalities can monitor 106 
biochemical processes as well as cross-sectional anatomy[38,39]. Though, they have certain 107 
limitations[40-42], which are either due to their intrinsic characteristics or the potentially harmful effect of 108 
the contrast agents. QD-based imaging technique could overcome these limitations, make it as one of the 109 
most promising technologies for early diagnosis of cancer[43,44].  110 
Glycans are carbohydrates that can be attached to proteins, lipids and other glycans through enzymic 111 
process known as glycosylation. Glycans have key roles in cancer biology, including cell signalling, 112 
tumorigenesis, immune modulation, angiogenesis and metastasis[45,46]. Aberrant changes in glycan 113 
structures have been shown to be associated with tumorigenesis, tumour progression and metastasis, thus 114 
a universal hallmark of cancer[46,47]. Compared to normal tissue, tumour cells have numerous changes 115 
in glycosylation, including changes to sialylation, fucosylation, the truncation of O-glycans, and N-glycan 116 
branching[47,48]. There is a huge potential to exploit glycans to improve early diagnosis, and as markers 117 
of specific therapeutic targets[45]. Lectin-QD bioconjugate could be an ideal tool to study glycan profile 118 
and glycosylation changes related to cancer. Table 1 presents a summary of Lectin functionalised QDs 119 
used for cancer diagnosis studies reported in literature. 120 
Table 1: Summary of lectin-functionalised QD conjugates for cancer diagnosis reported in literature. 121 
Application Carbohydrate detection Lectin Types of QDs Cancer model References 
Cancer diagnosis Glucose/mannose and L-fucose 
profile 
Con A, UEA I MSA-CdTe QDs Fibroadenoma and invasive ductal carcinoma 
cells 
[49] 
Cancer detection GalNAc , GlcNAc and mannose 
profiles 
DSA, LCA TGA-CdTe QDs HepG2 cells [50] 
Cancer diagnosis mannose/glucose, and galactose 
profile 
Cramoll CdTe QDs  [51] 
Cancer Theranostics  Mannose triflate, cysteamine 
molecules (MTC) 
SNA lectin  CdSe/CdS Caco-2, MCF-7 and A549 cells [52] 
Cancer Theranostics  - PHA-L  CdSe/CdS QDs MCF-7 cells [53] 
122 
2.1.1 Lectin functionalised QDs in Cancer Diagnosis  123 
Andrade et al.(2013)[49] formulated CdTe QDs functionalised with Mercaptosuccinic acid (MSA) and 124 
conjugated with Concanavalin A (Con A) or Ulex europaeus agglutinin I (UEA I) lectins to investigate 125 
conceivable variations in carbohydrates profile in normal breast tissue, fibroadenoma and invasive ductal 126 
carcinoma (malign tumour). These CdTe QDs are used to detect α-D glucose/mannose and L-fucose 127 
residues on cell surface. They showed to be more photostable and had higher luminescence intensity than 128 
the previously used glutaraldehyde CdS/Cd(OH)2 QDs[54]. They observed that the tissues stained with 129 
these CdTe QD conjugates showed different fluorescent patterns, which revealed distinct labelling patterns 130 
in the three tissue types. The stroma was favourably and intensely stained by CdTe QDs-Con A, due to 131 
higher expression of α-D-glucose/ mannose residues. The ductal cells were preferentially labelled by CdTe 132 
QDs-UEA I, revealing intense expression of L-fucose residues. These results indicate differences in 133 
expression and distribution of carbohydrate residues in these tissues. 134 
He et al.(2017)[50] synthesised hydrophilic thioglycolic acid (TGA) functionalised CdTe QDs 135 
conjugated with Datura stramonium agglutinin (DSA) and Lens culinaris agglutinin (LCA), which have 136 
different emission wavelength of 550 nm and 618 nm, respectively (Error! Reference source not 137 
found.AError! Reference source not found.). The formed functionalised QD-lectin bioconjugates are 138 
used to investigate the GalNAc and GlcNAc/mannose profiles on hepatocellular carcinoma cells (HepG2) 139 
by fluorescence imaging (Error! Reference source not found.BError! Reference source not found.) 140 
and flow cytometric analysis. Compared to normal endothelium cells (ECs) and liver cells (LO2), HepG2 141 
cancer cells labelled with QDs-DSA and QDs-LCA exhibited 3 and 2-fold greater signal, respectively. 142 
Thus, the lectin-QD bioconjugates proved to be efficient tools to monitor the carbohydrate expression and 143 
evaluating the differential expression of these carbohydrates on normal and cancer cells, which is very 144 
important for helping the early diagnosis of cancer.  145 
A recent study from Cunha et al. (2018) evaluated two different strategies to conjugate Cramoll lectin 146 
to QDs. Cramoll is a mannose/glucose–binding lectin with unique immunomodulatory and antitumor 147 
activities. Both adsorption and covalent bonding strategies have been used and tested at different pH 148 
values. The authors showed that QDs absorbed to Cramoll at pH 7.0 had the best labelling efficiency on 149 
Candida albicans cells. Approximately 92% of cells were labelled after incubation with adsorption 150 
conjugates compared to17% of cells were labelled by covalent conjugates. The Cramoll lectin and QD 151 
conjugates remained brightly fluorescent and preserved identical biological activity as Cramoll, thus it 152 
could be promising fluorescent tools for carbohydrate expression analysis in normal and cancer cells, 153 
which can provide valuable information about glycosylation changes related to cancer. 154 
 155 
Fig. 2 A) Schematic representation of lectin–QDs conjugates: QD550-DSA and QD618-LCA detecting 156 
cell surface carbohydrates. B) Fluorescence microscopy images of HepG2 cells stained by functionalised 157 
QDs. (Adapted with permission from Ref. [50]- Published by The Royal Society of Chemistry)   158 
2.1.2 Lectin functionalised QDs in Theranostics for Cancer  159 
Theranostics, is a term invented from merging diagnostics and therapeutics application of nanomaterials. 160 
QDs are excellent candidate for imaging and early cancer detection; they may also serve ideal delivery 161 
vehicles if the biocompatibility can be managed. Through surface functionalization of ligands and 162 
conjugation of “drugs” on QD one can construct an “all-in-one” multifunctional nanoplatform that features 163 
targeting, therapeutic and imaging modalities. lectin-QDs are showing promising results in theranostics 164 
applications. 165 
Akca et al.(2014)[52] synthesised CdSe/CdS QDs and conjugated with Sambucus nigra agglutinin 166 
(SNA) lectin and mannose triflate and cysteamine molecules (MTC). Cysteamine can induce apoptosis in 167 
cells, and its capacity can be increased with radiation. Biological activities of 125I-, 125I-MTCQDs, MTC-168 
QDs- Lec-125I, QDs-Lec-125I and Lec-125I were examined on various cancer cell lines such as Caco-2, 169 
MCF-7 and A-549. The results showed more specificity of SNA towards MCF-7 cells compared with 170 
other cells lines. In addition, the QDs-Lec-131I used in in vivo studies indicated that the conjugated QDs 171 
were accumulated in the liver and bladder. These results suggested that the conjugate QDs-Lec-125/131I 172 
presented both radioactive and fluorescent properties could be a useful tool for tumour imaging and 173 
radiotherapy.  174 
 175 
 176 
Kara et al.(2014)[53] prepared CdSe/CdS QDs, conjugated with PHA-L and labelled with 125I to study 177 
the interface between phytohemagglutinin-L (PHA-L) and sialic acid. Sialic acid is abundant on the breast 178 
cancer cell (MCF-7) surface. The authors demonstrated that 125I labeled QD-PHA-L conjugates represent 179 
significant affinity on MCF-7 cells and the cell incorporation increased with time. This result was also 180 
confirmed by computational simulation using crystal structure of PHA-L, which revealed that the 181 
conjugates had a significant affinity for cells. 182 
2.2 Carbohydrate-functionalised QDs in Cancer Diagnosis and Treatment 183 
Lack of specificity of formulated drug or nanomaterial is the major challenge for the effective cancer 184 
treatment. Therefore, the development of targeted system for cancer diagnosis and treatment is highly 185 
desirable. Cancer cell differ from its malignant counterparts, which provides valuable characteristic to 186 
develop specific targeted system for cancer. Targeted fluorescent biomarkers have found great advantage 187 
in the specific visualisation of cancer cells, which enables early-stage detection of cancers instead of 188 
depending on advanced morphological changes alone. Moreover, targeted system enhanced drug delivery 189 
to specific cancer cells or tissue thereby dramatically improving the selectivity and efficacy of anti-cancer 190 
drugs. Carbohydrates have attracted considerable attention in the development of targeting systems due to 191 
their ability to differentiate and recognise cells and the endocytic uptake resulting from specific 192 
carbohydrate–lectin interactions. Table 2 presents a summary of Carbohydrate-functionaslied QDs 193 
targeting different cancer models for potential cancer treatment discussed in the text below.194 
Table 2: Summary of Carbohydrate-functionalised QDs targeting various types of cancer reported in literature 195 
Applications Carbohydrate Types of QDs Targeting receptor Cancer model References 
Cancer imaging SialylLacNAc, LacNAc, Lex  PC-QDs  Mice model [55] 
Cancer cell imaging Mannose and Galactose CdSe/ZnS- TOPO QDs Asialoglycoprotein 
receptors 
HepG2 cells [56] 
Cancer cell imaging β-galactose and -glucose CdTe/CdS QDs Asialoglycoprotein 
receptors, Glucose receptor 
HepG2 cells [57] 
Cancer cell imaging α-glucose, α- N-acetylglucose, β-
galactose, Mannose or Sialic acid 
ZnS-AgInS2 QDs Asialoglycoprotein 
receptors 
Leukemia (THP-1), Macrophage 
(J774.A1) and HepG2 cells 
[58] 
Cancer cell imaging D-mannose Silicon QDs - MCF-7 cells [59] 
Cancer cell imaging Glucose, Lactose Silicon QDs - B16F10 melanoma cells [60] 
Cancer cell imaging Glucose Silicon QDs  HeLa cells [61] 
Cancer targeting Galactose CdTe/ZnS-TOPO Asialoglycoprotein 
receptors 
HeLa and A549 cells [62] 
Cancer targeting D-mannose Silicon QDs - MCF-7 cells [63] 
Cancer targeting Galactose, Glucose, Mannose, 
and Lactose 
Silicon QDs - MCF-7, HepG2, A549, SK-Mel, HHL5, 
HeLa cells 
[64] 
Cancer targeting Galactose CdSe-ZnS QDs Galactose receptors HepG2 and HeLa cells [65] 
Cancer Theranostics  Mannose Albumin-CdTe QDs  MCF-7 and MDA-MB-231 cells, Ehrlich 
ascites tumour in BALB/C mice 
[66] 
196 
 2.2.1 Carbohydrate-functionalised QDs for Cancer imaging 197 
Ohyanagi et al.(2011)[55] investigated the dynamic distribution profiles of Carbohydrate-functionalised QDs 198 
in model animals. The authors synthesised NIR fluorescent CdSeTe/CdS QDs and coated them with a mixed 199 
population of thiol. The obtained QDs were further coated with different carbohydrate to form a collection 200 
of Carbohydrate-functionalised QDs for in vivo study. NIR images of mice injected with carbohydrate-coated 201 
QDs exhibited significant differences in time-dependent distribution (Fig. 3). The authors demonstrated that 202 
Sialyl N-acetyllactosamine (sialylLacNAc) linked QDs accumulated in the spleen and intestine 2h post 203 
injection, while LacNAc-functionalized QDs and Lex-QDs were localised in the liver, and no preferential 204 
distribution was observed for sLex-QDs. These results suggest that the structure of the carbohydrate residues 205 
in the individual sialylated oligosaccharides might influence significantly the organ-specific distribution of 206 
the glycan functionalised QDs. 207 
 208 
Fig. 3 Live animal imaging module of mice treated with Glyco-functionalised QDs carrying Lewis antigen-related 209 
oligosaccharides. (Reproduced with permission from Ref. [55]. Copyright (2011) American Chemical Society.)  210 
It has been well reported in the literature that hepatocytes, especially hepatocellular carcinoma cells (e.g. 211 
HepG2) have overexpressed galactose receptors-Asialoglycoprotein receptors (ASGP-Rs)[67-71]. Thus, 212 
ASGP-Rs could be an ideal target for liver cancer cells[70,71]. Bavireddia and Kikkeri (2012)[56] 213 
synthesised β-cyclodextrin (β-CD) capped with O-α- mannopyranoside (man) and O-β-galactopyranoside 214 
(gal) to CdSe/ZnS- TOPO QDs. They first studied the interaction of synthesised nanoparticles with different 215 
lectins like ConA, Galanthus nivalis agglutinin (GNA) and Peanut agglutinin (PNA) and observed that QDs-216 
β-CD-man conjugates were successfully linked to ConA and GNA, while QDs-β-CD-gal conjugates only 217 
 showed affinity with PNA. They later introduced these multivalent fluorescent nanoparticles in HepG2 cells 218 
and observed that only β-CD-gal QDs internalized in liver carcinoma cells, which confirms 219 
Asialoglycoprotein receptor mediate interaction. Shinchi et al.(2012)[57] also proved similar concept by 220 
synthesizing β-galactose and -glucose CdTe/CdS QDs and studied there interaction with ConA and Ricinus 221 
communis agglutinin I (RCA 120). They proved that β-galactose CdTe/CdS QDs internalised in HepG2 cells, 222 
which express asialoglycoprotein receptors, whereas α-glucose QDs showed poor uptake in HepG2 liver 223 
carcinoma cells. They later then synthesised small library of cadmium free sugar ZnS-AgInS2 QDs such as 224 
α-glucose, α- N-acetylglucose, β-galactose, mannose or sialic acid.[58] They used three different cell lines, 225 
leukaemia (THP-1), macrophage (J774.A1) and HepG2 cells. The results showed that leukaemia cells only 226 
uptaken α-glucose QDs, perhaps due to the lack of carbohydrate receptors. All the QDs were internalised in 227 
Macrophage cells, whereas HepG2 cells were preferentially taken up β-galactose QDs, due to the high 228 
amount of asialoglycoprotein receptors in these cells’ membranes. 229 
Zhai et al.(2014)[59] have also developed a straightforward synthesis method for carbohydrate-230 
functionalised Silicon quantum dots (SiQDs). The authors used three surface modifications to study SiQDs 231 
solubility in water and their biocompatibility within cells: L-alanine and pentanoic acid were chosen for their 232 
structural simplicity and D-mannose surface functionalities were used for targeted imaging of MCF-7 breast 233 
cancer cells. Fluorescence microscopy demonstrated the D-mannose and L-alanine functionalised SiQDs 234 
could readily internalised by MCF-7 cells, however, the pentanoic acid terminated SiQD did not. This 235 
observation indicates carbohydrate-functionalised SiQDs can be effective luminescent imaging agents.  236 
Lai et al.(2016)[60] created structurally defined and fluorescently labelled multifunctional carbohydrate-237 
capped Silicon nanoparticles (SiNPs) to study ultra-weak carbohydrate−carbohydrate interactions by surface 238 
plasmon resonance (SPR) and cell imaging. An additional dye (ATTO647N) was added to create dual-239 
fluorescent SiNPs. They synthesised three different sugar-capped SiNPs (Glc-dye@SiNP, Lac-dye@SiNP, 240 
and Gg3-dye@SiNP) and subsequently used to determine the low-affinity interaction of the two 241 
glycosphingolipids GM3 and Gg3. Specific binding of Gg3-dye@SiNPs to immobilized GM3- biotin-PAA 242 
was detected, and affinity analysis was performed by SPR confirming the existence of this 243 
carbohydrate−carbohydrate interaction. Moreover, they demonstrated that sugar-dye@SiNPs are valuable 244 
tools for cell imaging by the uptake of Gg3-dye@SiNPs into GM3-expressing B16F10 melanoma cells (Fig. 245 
4). 246 
 247 
 Fig. 4 Confocal fluorescent images showing the uptake of Gg3-dye@SiNPs by B16F10 cells after 2h incubation. SiNPs 248 
inherent fluorescence-blue, DIC-differential interference contrast microscopy, Early endosomes-green (stained with an anti-249 
EEA1 antibody), actin cytoskeleton-red (stained with Alexa 555-labeled phalloidin). (Adapted with permission from Ref. 250 
[60]. Copyright (2016) American chemical society.) 251 
Hsu et al.(2017)[61] also synthesized ultra-small SiNPs (i.e. Silicon quantum dots, SiQDs) for cancer cell 252 
imaging purpose. The SiQDs were functionalised with glucose moieties on their surface (Si–Glc). The 253 
amount of glucose on the surface of SiQDs could be well controlled by varying the ratio between the amount 254 
of SiQDs and the saccharide groups during the coupling reaction. The photophysical behaviour of the glucose 255 
functionalised SiQDs were not significantly different to that of the unmodified nanoparticles. In vitro studies 256 
performed on HeLa cells demonstrated faster internalisation (1 hour) of Si-Glc into the cells compared to the 257 
unmodified NPs (24 hours). Furthermore, CASY assay showed that Si-Glc exhibited high cell viability. 258 
These findings suggested these glucose functionalised SiQDs could be potentially interesting alternatives as 259 
cancer bioimaging probes. 260 
2.2.2 Carbohydrate-functionalised QDs for Cancer targeting and theranostics 261 
Cheng et al.(2013)[62] developed hydrophilic L-cysteine coated CdSeTe QDs conjugated with Con A, and 262 
then with N-acetylglucosamine (GlcNAc). The QDs-ConA-GlcNAc bioconjugate was formed by lectin–263 
carbohydrate interaction between Con A and GlcNAc. GlcNAc possesses a strong affinity for Hsp70 (70 kDa 264 
Heat Shock Protein), an important protein involved in tumour cell proliferation and may be a potential 265 
biomarker for cancer cells[62,72-74]. The obtained bioconjugates has an emission wavelength at 650 nm and 266 
displayed a high fluorescence intensity with specific binding to HeLa cells (cervical cancer cells). The co-267 
localization of red fluorescence from QDs-Con A-GlcNAc bioconjugate with the green fluorescence from 268 
FITC- Immunoglobulin G suggested that these Glyo-QDs can target the Hsp70 protein. These results show 269 
that the QDs-Con A-GlcNAc bioconjugate can be a promising tool for direct localisation of the Hsp70 270 
protein, therefore recognise cancers related to this protein. 271 
Ahire et al.(2013)[63] developed D-mannose capped Silicon nanoparticles (SiNPs) for targeting MCF-7 272 
breast cancer cells. Visualisation imaging of SiNPs in MCF-7 human breast cancer cells showed the 273 
fluorescence was distributed throughout the cytoplasm of these cells. Later the same research group prepared 274 
SiNPs capped with different carbohydrates including galactose, glucose, mannose, and lactose from amine 275 
terminated SiNPs[64,75]. The MTT analysis showed an extensive reduction in toxicity of SiNPs by 276 
functionalizing with carbohydrate moiety in vitro. In vivo toxicity assay on the X. laevis embryos showed 277 
that carbohydrate capped SiNPs do not induce severe toxicity, however the amine terminated SiNPs caused 278 
the death of the embryos (Fig. 5A). They reported that the carbohydrate-functionalised SiNPs internalized in 279 
the cells within 24 hours of incubation and reached the optimal concentration within the cells (Fig. 5B). 280 
Furthermore, they showed a reduced internalization of the carbohydrate-functionalised SiNPs at 4°C 281 
compared to 37°C, which suggested the cellular uptake of the carbohydrate capped SiNPs is likely to be 282 
receptor-mediated and energy dependent. They also showed that the up-taken of the carbohydrate capped 283 
SiNPs were more readily by cancer cells (A549, MCF-7 and SK-Mel28) than non-cancerous cells (MDCK 284 
and HHL5, Fig. 5C). Moreover, they demonstrated the use of carbohydrates for the internalisation of a variety 285 
of similar compounds into cancer cells. 286 
  287 
Fig. 5 A) In vivo toxicity assay using X. laevis embryos. Embryos exposed to carbohydrate capped SiNPs at a concentration 288 
of 200 μg mL−1 a) control, b) gal capped SiNPs, c) man capped SiNPs, d) Glu capped SiNPs, e) Lac capped SiNPs, and f) 289 
amine‐terminated SiNPs. Embryos were exposed to the SiNPs at NF stage 15 and scored at NF stage 38. B) Time dependent 290 
uptake efficiency of carbohydrate capped SiNPs in SK-Mel28 cells at various incubation times. C) Uptake efficiency of 291 
carbohydrate capped SiNPs in cancer cells (A549, SK-Mel28, and MCF-7) and noncancerous cells (MDCK, HHL5) at 24 292 
hours. (Copyright Wiley. Adapted with permission from Ref.[64]) 293 
It is well known that galactose receptors are overexpressed in certain types of cancer cells, for example 294 
hepatocellular carcinoma[70,71]. However, the role of galactose multivalency on cellular processes are 295 
largely unexplored. To study these, Dalal and Jana (2018)[65] have synthesised galactose functionalised 296 
multivalent QDs with the average numbers of galactose per QD of 25, 50, and 80 [QD(gal)25, QD(gal)50, 297 
and QD(gal)80]. The uptake mechanism of the multivalent QDs were investigated in galactose receptor 298 
overexpressed HepG2 cells. The authors have demonstrated that the cellular interaction and uptake kinetics 299 
of these galactose functionalised QDs increased with increasing galactose multivalency, while the uptake 300 
mechanism shifts from lipid raft/caveolae-mediated endocytosis to clathrin-mediated endocytosis as 301 
galactose multivalency increased. They have also found that lower multivalent QDs reside in the cytoplasm 302 
for a longer time compared to higher multivalent QDs, but their endosomal/lysozomal trapping and 303 
exocytosis increased as increasing galactose multivalency. The demonstrated finding is agreed with the 304 
extensive study done by Zhang and Monteiro-Riviere[76]. They have demonstrated that the uptake of un-305 
conjugated QDs probably regulated via lipid raft/caveolae-mediated endocytosis. They also showed that after 306 
internalisation into the cytoplasm, the QDs entered early endosomes and then transferred into late endosomes 307 
or lysosomes. In addition, they showed that QD endocytic pathway is primarily regulated by the G-protein 308 
coupled receptor associated pathway. These findings demonstrate the functional role of galactose 309 
multivalency on cellular interaction, cell uptake mechanism, and subcellular targeting, which could be 310 
proposed for subcellular targeting applications. 311 
By combining the carbohydrate specific targeting towards cancer cells and strong fluorescence imaging 312 
capability of QDs, Zayed et al.(2019)[66] have developed a smart cancer nano-theranostics system. The 313 
 authors attached both biocompatible albumin backbone and mannose moieties to CdTe QDs for enhanced 314 
tumour targeting and reduced QDs toxicity. They have then used a combination therapy that co-loading 315 
anticancer drug pemetrexed (PMT) and resveratrol (RSV) to the QD platform for tumour site-specific release. 316 
The mannose functionalised Albumin–QDs theranostics could be tracked by their high fluorescence quantum 317 
yield and showed enhanced cytotoxicity and internalization into MCF-7 and MDA-MB-231 breast cancer 318 
cells. Moreover, in vivo bioimaging demonstrated excellent tumour-specific accumulation of the mannose-319 
grafted theranostic QDs. The theranostic QDs also showed effective anti-tumour activities including reduced 320 
tumour volume, increased apoptosis, and inhibited angiogenesis. Overall, mannose-grafted theragnostic QDs 321 
nanoplatform could be a potential nano-theranostic for bioimaging and targeted breast cancer therapy.   322 
3 Challenges Faced in using Glyco-functionalised QDs in Biomedical 323 
Applications 324 
3.1 Nanotoxicology 325 
Despite of QDs showing great potential for biomedical imaging and detection, limitation of its application 326 
arises mainly from heavy metal, colloidal instability and oxidation of the nanoparticle core/shell material, 327 
which constraint the improvement towards the diagnosis and therapy of cancer. These concerns serve as great 328 
barrier for human application in vivo cancer imaging than the development of the application in vitro. Huge 329 
efforts have been made to generate novel QDs that minimize toxicity and maximize detection efficiency by 330 
changing their components such as sizes, surface coatings, and valences etc. Nanoparticles coating is a 331 
promising approach to reduce the cytotoxicity because these additional layers act as a physical barrier to the 332 
core/shell to prevent oxidation. Ligand show a negative charge at biological pH have been widely used for 333 
solubilisation of QDs including carboxylic acid, hydroxyl or amine groups. PEG coated QD has been proven 334 
to be remarkably stable and almost completely removed cytotoxicity. However, such surface modification 335 
reveals reduced uptake by cells compared to other surface coatings. It is important to know that layers of 336 
coating should not only protect the QD core/shell from oxidation but must also proliferate the cellular uptake.  337 
Simply adding more layers to achieve desirable results is not a favourable strategy for biological applications, 338 
because it will largely increase the size of the QDs and become an issue.  339 
Carbohydrate-functionalised nanomaterials showing outstanding biocompatibility, biodegradability, high 340 
diversity of chemical functionalities, and versatile biological functions in Biomedical applications. The study 341 
of glyconanomaterials, on the other hand, is a new field and the progress has been relatively covering. The 342 
vast majority of glyconanomaterial are made from simple, low-cost carbohydrate structure such as 343 
monosaccharides. The conjugation process is mostly general chemistry and can be useful to attach these 344 
carbohydrates to an extensive diversity of nanomaterials. Glyconanomaterial act as a multivalent scaffold 345 
carrying multiple copies of carbohydrate molecules, thus elaborating the binding affinity with the recognition 346 
receptors. It has been reported that carbohydrate-functionalised QDs show no/minimal cytotoxicity both in 347 
vivo and in vitro environment. This carbohydrate functionality not only act as physical barrier to provide 348 
stability but also serves a specific targeting ligand. 349 
Nevertheless, few additional objectives should also be considered such as coating shell degradation caused 350 
by modification of QDs, nonspecific accumulation by liver, spleen and lymphatic system, immune response 351 
and genotoxic effect etc. Considering the toxicity of Cd, Se, Zn, Te, Hg, and Pb, several low toxicity QDs 352 
 have been established as substitutes. For example, carbon dots (CDs) less than 10 nm appear to be an ideal 353 
alternative to Cd2/Pb based semiconductor QDs for their tunable stable fluorescence emission, low cost, and 354 
low toxicity[77]. The same group have also synthesised graphene quantum dots (GQDs) for direct and 355 
efficient stem cell labelling[78] and cancer diagnosis [79]. Non-toxic elements doping could be another way 356 
to achieve low toxicity. These doped QDs have tunable fluorescence and high quantum efficiency and are 357 
ideal candidates for biomedical applications. Silicon QDs are exceptional candidate and have been showing 358 
promising results in reduced cytotoxicity[75,80]. For in vivo applications, Silicon NPs provide attractive 359 
chemical alteration to heavy-metal containing QDs, which are shown to be toxic in biological environments. 360 
In addition silicon is a common trace element in human body, it is reported that silicic acid administrated to 361 
human is efficiently excreted from the body through urine[81]. It can be expected that multifunctional, non-362 
toxic silicon nanostructure in future may provide promising application in clinical translation. Nevertheless, 363 
before employing QDs in any medical procedure extensive analysis and research on the toxicity profiles will 364 
be needed. Further studies are also needed to investigate the long-term toxicology and pharmacokinetics of 365 
QDs from living systems involving degradation, clearance, persistence, and immune response of QDs.  366 
3.2 Design and Generation of Biocompatible and Biodegradable Glyco-367 
functionalised QDs 368 
The current limitation of QDs in vivo imaging is due to the non-specific organ uptake and reticuloendothelial 369 
system (RES) scavenging, which are mainly because of large size, colloidal instability and short circulation 370 
half-life in the blood vascular system. A number of literature demonstrated the fate of QDs in vivo has been 371 
affected by particle size and surface functionality[82-84]. Choi et al[85] have defined the requirements for 372 
renal filtration and urinary excretion of QD using rodents as a model system. They have also suggested to 373 
use zwitterionic or neutral organic coatings to prevent adsorption of serum proteins, which otherwise 374 
increased QD’s hydrodynamic diameter and prevent renal excretion. The author concluded that the size of 375 
QD should be controlled under 5.5 nm to achieve efficient urinary excretion and elimination of QDs. These 376 
findings have also been confirmed by other group, for example Cai et al[86] showed that the QD size less 377 
than 5 nm was mainly found in the bladder at 4 hours after intravenous injection, while QDs larger than 5 378 
nm accumulated primarily in the lung, spleen, and liver, indicating a different excretion pattern. 379 
 Continuous efforts are attempted to prevent adsorption of QDs to the plasma proteins and prolong their 380 
circulation time by coating them with passivating molecules. The multivalent effect of glyconanomaterial 381 
increases the binding affinity with the recognition receptors, thus it is considered as simple glycan-presenting 382 
cell/virus-mimics able to interact with other biological entities. Compared to free, unbound carbohydrates, 383 
Glyco-functionalised QDs exhibit several orders of magnitude higher binding affinity with lectins. However, 384 
the multivalent effect is dependent on several factors including conjugation chemistry, spacer linkage, ligand 385 
density and spatial arrangement. In order to produce effective Glyco functionalised QDs for biomedical 386 
application, comprehensive understanding of all these issues is needed. 387 
The unique physical properties of nanomaterial and recognition ability of carbohydrate ligands provide 388 
benefit to glyconanomaterial in biomedical application. Carbohydrate ligands selectively interact with the 389 
receptors on cell surface, and trigger binding, cell agglomeration, or particle internalisation. Altogether with 390 
Glyco functionalisation and unique physical properties of nanomaterial advance to translate molecular events 391 
into noticeable or clear signals allowing for imaging and revealing of disease state. These glyconanoparticles 392 
have been used in fluorescence, Magnetic Resonance Imaging (MRI) and Positron Emission Tomography - 393 
 Computed Tomography (PET/CT) imaging to distinguish normal and cancer cell lines or to detect tumours. 394 
Glyconanomaterials have demonstrated promising results in biocompatibility. Recent studies by Vela-395 
Ramirez et al.[87] reported the safety and biocompatibility of carbohydrate-functionalized polyanhydride 396 
nanoparticles upon parenteral and intranasal administration. The results showed that a 5-mg dose of either 397 
linker- or di-mannose-functionalised nanoparticles did not induce hepatic or renal tissue damage or cause 398 
elevation of damage-related or functional biomarkers in serum or urine following subcutaneous 399 
administration. 400 
3.3 Reproducibility, Reliability, and Comparability of Glyco-functionalised QDs 401 
The major limitation of QDs when using in clinical application is their reproducibility and comparability as 402 
well their potential for quantification. Glyco-functionalised QDs are showing promising results for 403 
biomedical applications however there is insufficient amount of data on their reproducibility and 404 
comparability. Different functionalisation from various carbohydrate will results in different quantum yield 405 
based on various material and surface chemistries. Moreover, the absolute control on quantification of 406 
carbohydrate moiety on the surface of QDs is also in need when using surface chemistry. Purity is also one 407 
of the concerns when applying Glyco-functionalised QDs in clinical trial. Thus, the origin and establishment 408 
of quality standards for these advance materials of various carbohydrate-functionalised QDs is the essential 409 
initial step in targeting cancer.  410 
4 Future Perspective 411 
In the near future the research of glycol-conjugated QDs in cancer imaging will significantly improve their 412 
clinical application in targeting metastasis and in quantitative measurement of molecular targets. The ongoing 413 
development of Glyco-functionalised QDs can target solid tumour tissues with mature vasculature, however 414 
it is challenged to target micro-metastasis without well-developed vasculature.  Therefore, the surface of 415 
Glyco functionalised QDs needs to be further engineered to enable efficient extravasation, to reach micro-416 
metastasis and initiate binding to tumour antigens. The progressive research in glyco-conjugated QDs will 417 
improve early cancer detection and their clinical application in targeting metastasis tumour in near future. 418 
The ongoing development of glyco-functionalised QDs can target solid tumour tissues, however it is still 419 
challenged to target micro-metastatic tumour.  Therefore, it is important to further engineered the 420 
carbohydrate moiety’s to target specific micro-metastasis tumour and initiate binding with antigens. It is also 421 
important to minimize the RES uptake and maximize the tumour specific uptake by engineering tumour 422 
specific targeting carbohydrate moiety on the surface of QDs. Because metastasis is possible in RES system, 423 
especially in liver and lymph node, non-specific RES uptake will result in false-positive results. Long 424 
circulation time in blood and colloidal stability is also another important aspect; moreover, it also helps in 425 
reducing RES uptake. Glycosilyated PEG proves to be good candidate for longer circulation in blood and 426 
minimizing RES uptake nonetheless finally size can become issue. When using for biomedical application 427 
or cancer therapy, systemic toxicity is an important feature. QD toxicity is well known and it is still a topic 428 
of concern, however it has shown that carbohydrate functionality helps reducing nanoparticle toxicity. 429 
Perhaps Silicon QDs will emerge as a striking substitute to heavy metal-containing QDs, due to lower toxicity 430 
potential, and progress further biological and clinical applications. Optimal clearance of modified QDs from 431 
body is additional issue, which needs to be address; toxicity is also induced by poor clearance from body. 432 
 Thus, it would be viable to design and create such promising therapeutic agent with more favourable 433 
clearance properties.  434 
5 Conclusions 435 
Glyconanotechnology’s emerging progress in cancer therapy, diagnosis and theranostic applications have 436 
revolved these nanoprobes very attractive branch of the world scientific research. Combining these tools 437 
along with unique fluorescent characteristic of QDs and specificity of carbohydrate functionality enabling 438 
real-time studies, introducing new opportunities for several biomedical applications. More theranostic 439 
applications could be developed by selecting and engineering specific tumour carbohydrate functionality 440 
along with unique featured QDs. 441 
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